PBLA - Panbela surges 19% on starting phase II trial of CPP-1X-T for type I diabetes

• Panbela Therapeutics ( NASDAQ: PBLA ) is trading ~19% higher after it begun a Phase II study to test CPP-1X-T (Eflornithine tablets) for type 1 diabetes, in collaboration with Indiana University School of Medicine.
• The study will test patients with recent onset type 1 diabetes and will randomize participants 2:1 to CPP-1X-T, administered orally with food, twice daily, at a dose of 1000 mg/m2, or placebo over 6 months followed by a 6 month wash out period to assess durability of response.
• Indiana University expects to enroll 70 patients in the Phase II clinical trial at about 6 centers in the United States.

For further details see: